An investor of former Turing Pharmaceuticals CEO Martin Shkreli's hedge fund, in a testimony revealed that despite investing under Shkreli's false claims, he eventually made millions of dollars from the investment. Shkreli, who is now facing a fraud trial, had paid off the investors through an agreement in which he gave them shares in his drug company Retrophin.